ubiprostone phase 3 double-blind study
Phase 3
- Conditions
- chronic idiopathic constipation
- Registration Number
- JPRN-jRCT2080220730
- Lead Sponsor
- Sucampo Pharma, Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 116
Inclusion Criteria
history of fewer than three spontaneous bowl movements (SBMs) per week for at least six months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change in SBMs at the end of the first week of treatment
- Secondary Outcome Measures
Name Time Method